|
Evaxion Biotech A/S (EVAX): Marketing Mix [Jan-2025 Updated]
DK | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Evaxion Biotech A/S (EVAX) Bundle
In the cutting-edge world of biotechnology, Evaxion Biotech A/S emerges as a pioneering force, leveraging artificial intelligence to revolutionize personalized immunotherapy. With its innovative AI-powered platform targeting cancer and infectious diseases, the Danish company is pushing the boundaries of precision medicine, transforming how we approach therapeutic development through advanced computational algorithms and a strategic global approach. Dive into the comprehensive marketing mix that reveals how this dynamic biotech innovator is positioning itself to potentially reshape the future of medical treatments.
Evaxion Biotech A/S (EVAX) - Marketing Mix: Product
AI-Powered Precision Immunotherapy Platform
Evaxion Biotech develops AI-driven immunotherapy solutions targeting cancer and infectious diseases. The company's proprietary AI platform enables computational design of personalized vaccine and immunotherapy candidates.
| Platform Technology | Key Capabilities |
|---|---|
| AI Immunology Algorithms | Machine learning-based antigen identification |
| Computational Design | Personalized vaccine candidate generation |
| Predictive Modeling | Immune response prediction |
Clinical-Stage Pipeline Products
Evaxion's product portfolio focuses on two primary therapeutic domains:
- Oncology immunotherapies
- Infectious disease vaccines
| Product | Disease Target | Development Stage |
|---|---|---|
| EVX-01 | Melanoma | Phase 1/2 Clinical Trial |
| EVX-02 | Solid Tumors | Preclinical Development |
| EVX-03 | Infectious Diseases | Research Stage |
Computational Drug Discovery Approach
Evaxion utilizes advanced AI algorithms for comprehensive drug discovery and design processes.
- Machine learning-based antigen identification
- Predictive immune response modeling
- Personalized vaccine candidate generation
Evaxion Biotech A/S (EVAX) - Marketing Mix: Place
Headquarters Location
Evaxion Biotech A/S is headquartered at Kogle Allé 4, 2970 Hørsholm, Denmark.
Research and Development Operations
Research and development operations are concentrated in the Scandinavian region, specifically in Denmark.
| Location | Operational Focus | Geographic Scope |
|---|---|---|
| Hørsholm, Denmark | Primary R&D Center | Scandinavian Region |
Global Collaboration Strategy
Key Pharmaceutical and Research Partnerships
- United States research institutions
- European pharmaceutical networks
- International immunotherapy research centers
Target Markets
| Market | Market Penetration Strategy | Primary Focus |
|---|---|---|
| United States | Direct pharmaceutical market engagement | Immunotherapy development |
| European Markets | Collaborative research partnerships | AI-driven drug discovery |
Distribution Channels
- Direct sales to pharmaceutical companies
- Research collaboration platforms
- International biotechnology conferences
Evaxion Biotech A/S (EVAX) - Marketing Mix: Promotion
Scientific Conference Presentations and Academic Publications
Evaxion Biotech A/S actively participates in scientific conferences to showcase its AI-driven immunotherapy research. In 2023, the company presented at the following key conferences:
| Conference | Date | Location | Presentation Focus |
|---|---|---|---|
| American Association for Cancer Research (AACR) | April 2023 | Orlando, FL | AI-powered vaccine development |
| Society for Immunotherapy of Cancer (SITC) | November 2023 | San Diego, CA | Precision immunotherapy platforms |
Investor Relations Communications
Evaxion Biotech utilizes multiple communication channels for investor outreach:
- Quarterly earnings reports filed with NASDAQ
- Press releases distributed through Business Wire
- Investor presentations with 4 quarterly updates in 2023
| Communication Type | Frequency | Platform |
|---|---|---|
| Earnings Calls | 4 times per year | NASDAQ Investor Relations Portal |
| Press Releases | 12 releases in 2023 | Business Wire |
Digital Marketing Channels
Evaxion maintains a comprehensive digital presence:
- Company website: evaxion-ai.com
- LinkedIn Company Page followers: 3,421 as of January 2024
- Twitter followers: 1,872 as of January 2024
Partner and Investor Outreach
Strategic engagement with potential pharmaceutical partners and investors includes:
- Targeted pharmaceutical partnership meetings: 6 in 2023
- Investor roadshow presentations: 3 in 2023
- Biotech investment conferences attended: 2 in 2023
| Outreach Activity | Number in 2023 | Target Audience |
|---|---|---|
| Pharmaceutical Partnership Meetings | 6 | Potential Pharma Collaborators |
| Investor Roadshow Presentations | 3 | Institutional Investors |
Evaxion Biotech A/S (EVAX) - Marketing Mix: Price
Financial Overview
As of Q4 2023, Evaxion Biotech A/S operates as a pre-revenue biotechnology company with the following financial characteristics:
| Financial Metric | Value |
|---|---|
| Market Capitalization | $25.6 million |
| Cash and Cash Equivalents | $14.3 million |
| Net Loss (2023 Fiscal Year) | $12.7 million |
| Stock Price (NASDAQ: EVAX) | $1.47 per share |
Funding Strategy
Evaxion's pricing strategy is primarily focused on research and development funding through multiple channels:
- Venture Capital Investments
- Public Market Financing
- Research Grants
- Potential Collaborative Research Agreements
Funding Sources
| Funding Source | Amount Raised | Year |
|---|---|---|
| Venture Capital | $8.5 million | 2023 |
| Public Offering | $6.2 million | 2023 |
| Research Grants | $1.6 million | 2023 |
Pricing Approach
Current pricing strategy is centered on potential future value of therapeutic pipeline, with focus on:
- Immunotherapy development
- AI-driven drug discovery platforms
- Potential licensing of proprietary technologies
Stock Performance Metrics
| Performance Indicator | Value |
|---|---|
| 52-Week Low | $0.85 |
| 52-Week High | $2.15 |
| Average Trading Volume | 125,000 shares |